NeoGenomics (NEO) COO logs RSU vesting and tax share withholding
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
NeoGenomics President & Chief Operating Officer Warren Stone reported equity award vesting and related share-withholding transactions. On February 21 and 23, 2026, restricted stock units converted into 36,548 shares of common stock at no cash exercise price.
To cover tax obligations tied to these RSU releases, 10,465 common shares were disposed of through issuer share withholding rather than open-market sales. Following these transactions, Stone directly owned 147,714 shares of NeoGenomics common stock, along with various stock option, restricted stock unit, and performance stock unit holdings described in the filing footnotes.
Positive
- None.
Negative
- None.
Insider Trade Summary
36,548 shares exercised/converted
Mixed
19 txns
Insider
Stone Warren
Role
Pres & Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 8,443 | $0.00 | -- |
| Exercise | Common Stock | 8,443 | $0.00 | -- |
| Tax Withholding | Common Stock | 3,323 | $0.00 | -- |
| Exercise | Restricted Stock Unit | 28,105 | $0.00 | -- |
| Exercise | Common Stock | 28,105 | $0.00 | -- |
| Tax Withholding | Common Stock | 7,142 | $0.00 | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Performance Stock Unit | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Performance Stock Unit | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Performance Stock Unit | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Unit — 8,443 shares (Direct);
Common Stock — 151,037 shares (Direct);
Stock Option (Right to Buy) — 166,113 shares (Direct);
Performance Stock Unit — 21,204 shares (Direct)
Footnotes (1)
- Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. On February 21, 2025, Mr. Stone was granted 84,317 restricted stock units. At the time of the grant, the restricted stock units vested ratably over the first three anniversary dates of the grant date. In connection with Mr. Stone'spromotion to President & Chief Operating Officer on April 1, 2025, the vesting schedule of these restricted stock units was modified so that they now vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grantdate. Once vested, the shares of common stock are not subject to expiration. On February 23, 2024, Mr. Stone was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. On December 1, 2022, Mr. Stone was granted 166,113 stock options. The options vest ratably over the first four anniversary dates of the grant date. On May 11, 2023, Mr. Stone was granted 53,969 stock options. The options vest ratably over the first three anniversary dates of the grant date. On May 11, 2023, Mr. Stone was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is31,806. The number of performance stock units that may vest is based on the achievement of certain growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company. On May 11, 2023, Mr. Stone was granted 28,838 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. On February 23, 2024, Mr. Stone was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date. On February 23, 2024, Mr. Stone was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. On May 2, 2024, Mr. Stone was granted 29,976 stock options. The options vest ratably over the first three anniversary dates of the grant date. On May 2, 2024, Mr. Stone was granted 17,905 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. On May 2, 2024, Mr. Stone was granted 17,908 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is26,862. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%. On February 21, 2025, Mr. Stone was granted 143,266 stock options. At the time of the grant, the options vested ratably over the first three anniversary dates of the grant date. In connection with Mr. Stone's promotion to President &Chief Operating Officer on April 1, 2025, the vesting schedule of these options was modified so that they now vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date. This stock option was granted as a premnium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%. On April 1, 2025, Mr. Stone was granted 94,518 stock options. The options vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date. On April 1, 2025, Mr. Stone was granted 52,687 restricted stock units. The restricted stock units vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date.
FAQ
What equity transactions did NeoGenomics (NEO) executive Warren Stone report on this Form 4?
Warren Stone reported vesting of restricted stock units converting into common stock and related share withholding for taxes. On February 21 and 23, 2026, RSUs converted into 36,548 common shares, while 10,465 shares were withheld to satisfy tax obligations associated with these equity awards.
What do the footnotes say about Warren Stone’s restricted stock units at NeoGenomics (NEO)?
The footnotes explain that each restricted stock unit equals one share of NeoGenomics common stock and converts upon vesting. They detail several RSU grants, vesting over three years or modified to 12-, 18-, and 24-month schedules, with vested shares no longer subject to expiration.
How were Warren Stone’s NeoGenomics (NEO) RSU vesting schedules modified after his promotion?
For certain February 21, 2025 RSU and stock option grants, vesting originally occurred annually over three or four years. After Stone’s promotion to President & Chief Operating Officer on April 1, 2025, vesting was changed to occur ratably at 12-, 18-, and 24-month anniversaries.
What are the performance stock units disclosed for Warren Stone at NeoGenomics (NEO)?
Performance stock units represent shares that may vest if performance goals are met. Footnotes describe grants in 2023 and 2024 with target share amounts and higher maximums, tied to stock-price growth and revenue growth metrics over specified measurement periods, contingent on continued service.